Neuland Laboratories Ltd Q3FY21 consolidated PAT rises to Rs. 26.73 crore

NEULAND LABORATORIES LTD. has reported financial results for the period ended December 31, 2020.

Financial Results (Q3 FY20-21) - QoQ Comparison

The company has reported total income of Rs.245.58 crores during the period ended December 31, 2020 as compared to Rs.241.99 crores during the period ended September 30, 2020.

The company has posted net profit / (loss) of Rs.26.73 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.21.44 crores for the period ended September 30, 2020.

The company has reported EPS of Rs.20.84 for the period ended December 31, 2020 as compared to Rs.16.71 for the period ended September 30, 2020.

Financials	Q3 FY20-21	Q2 FY20-21	% Change
Total Income	₹ 245.58 crs	₹ 241.99 crs	1.48%
Net Profit	₹ 26.73 crs	₹ 21.44 crs	24.67%
EPS	₹ 20.84	₹ 16.71	24.72%

Financial Results (Q3 FY20-21) - YoY Comparison

The company has reported total income of Rs.245.58 crores during the period ended December 31, 2020 as compared to Rs.204.86 crores during the period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.26.73 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.11.11 crores for the period ended December 31, 2019.

The company has reported EPS of Rs.20.84 for the period ended December 31, 2020 as compared to Rs.8.66 for the period ended December 31, 2019.

Financials	Q3 FY20-21	Q3 FY19-20	% Change
Total Income	₹ 245.58 crs	₹ 204.86 crs	19.88%
Net Profit	₹ 26.73 crs	₹ 11.11 crs	140.59%
EPS	₹ 20.84	₹ 8.66	140.65%

Financial Results (9 Months ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.693.70 crores during the 9 months period ended December 31, 2020 as compared to Rs.573.17 crores during the 9 months period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.63.33 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.25.50 crores for the 9 months period ended December 31, 2019.

The company has reported EPS of Rs.49.37 for the 9 months period ended December 31, 2020 as compared to Rs.19.88 for the 9 months period ended December 31, 2019.

Financials	9 Months ended FY20-21	9 Months ended FY19-20	% Change
Total Income	₹ 693.70 crs	₹ 573.17 crs	21.03%
Net Profit	₹ 63.33 crs	₹ 25.50 crs	148.35%
EPS	₹ 49.37	₹19.88	148.34%

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said "We are pleased to announce another strong quarter of top line and bottom line performance. The revenue at Rs.245.6 crores was a 20% improvement over the corresponding quarter of the last fiscal while the margins have showed an upward trajectory and closed at 19.0%. This was driven by growth across the GDS and CMS verticals. We remain confident of our long-term growth aspirations as well as our margin resilience."

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added "We are pleased with the momentum shown by the CMS business while the GDS also continues to play an important part in the growth. The driver of this quarter's CMS uptick has been the strong performance from the scaleup projects which have contributed to the revenues. Unit 3 has started commercial production and we are currently shipping out 2 API's from this facility. We expect Unit 3 to be a major driver of our growth going forward."

Shares of NEULAND LABORATORIES LTD. was last trading in BSE at Rs.1329.85 as compared to the previous close of Rs. 1286.65. The total number of shares traded during the day was 8738 in over 992 trades.

The stock hit an intraday high of Rs. 1355.25 and intraday low of 1276.4. The net turnover during the day was Rs. 11619084.

Source : Equity Bulls

Keywords